ArticlePloS one2026
Multifaceted bioactivity of brown seaweed-derived fucoidan from the Indian Coastline: A natural health product candidate.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brown seaweeds are rich in bioactive constituents, among which fucoidan a sulphated polysaccharide is particularly noted for its broad-spectrum therapeutic properties. This study explores the multifaceted bioactivity of fucoidan extracted from six brown seaweed species (Sargassum wightii, Sargassum tenerrimum, Sargassum cinereum, Turbinaria conoides, Padina boergesenii, and Padina tetrastromatica) collected from the Pudumadam coast, Gulf of mannar region, Tamil Nadu, India. Fucoidan was isolated and structurally characterized using Fourier-transform infrared spectroscopy (FT-IR) and nuclear magnetic resonance (NMR) spectroscopy. The antioxidant capacity of the extracts was assessed through 2,2-diphenyl-1-picrylhydrazyl (DPPH), hydroxyl radical scavenging activity (HRSA), and ferric reducing antioxidant power (FRAP) assays, with Sargassum cinereum showing the highest antioxidant activity (IC₅₀: 0.342 ± 0.01 mg/ml for DPPH; 1.26 ± 0.02 mg/ml for HRSA; 33.17 ± 0.02 mM Fe (II)/g for FRAP). In vitro antidiabetic assays demonstrated that fucoidan from Sargassum wightii exhibited the strongest inhibition of α-amylase and α-D-glucosidase (IC₅₀: 0.042 ± 0.02 mg/ml). Additionally, fucoidan from S. wightii displayed significant cytotoxic activity against MCF-7 human breast cancer cells. These findings underscore the therapeutic promise of brown seaweed-derived fucoidan as a multifunctional agent, supporting its potential application in the formulation of natural health products.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.